Bookmark

Add to MyYahoo RSS

Novo Nordisk AS News

News on Novo Nordisk AS (Ticker: NVO) continually updated from thousands of sources around the net.

Yesterday | In-PharmaTechnologist.com

Novo Nordisk defiant despite $90,000 disclosure fine

Novo Nordisk wants " a political debate " and changes to financial disclosure laws after Danish authorities fined it $90,000 for not immediately telling investors the US FDA had rejected Tresiba and Ryzodeg in 2013.

Comment?

Related Topix: Biotech, Food and Drug Administration

Mon Aug 18, 2014

Reuters

Denmark's Novo Nordisk accepts fine for late disclosure of drug setback

Novo Nordisk A/S said on Monday it had accepted a near $90,000 fine from Danish regulators for failing to inform investors quickly enough that a drug it had hoped would become its next growth driver had been refused U.S. approval.

Comment?

Related Topix: Biotech, Food and Drug Administration, Medicine, Health, Diabetes

Fri Aug 15, 2014

The Miami Herald

Kimball teams with Wilkins on diabetes awareness

IndyCar driver Charlie Kimball is teaming with NBA great Dominque Wilkins at this weekend's race at the Milwaukee Mile.

Comment?

Related Topix: Biotech

Thu Aug 14, 2014

Insider Monkey

McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO),...

Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons ' Renaissance Technologies , one of the best performing firms in the sector.

Comment?

Related Topix: Biotech, Restaurant Management, Mcdonalds, Financial Services, Renaissance Technologies, Investment Services

Tue Aug 12, 2014

AmericanBankingNews.com

Novo Nordisk A/S Stock Rating Reaffirmed by Zacks

's stock had its "neutral" rating reiterated by Zacks in a research report issued on Tuesday.

Comment?

Related Topix: Biotech

Mon Aug 11, 2014

Resource Investing News

CSE Top 5: Choice Gold, Rosehearty Energy Top Gainers

Several companies listed on the Canadian Securities Exchange had an eventful week.

Comment?

Related Topix: Biotech, South America, World News, Guyana

Seeking Alpha

Novo Nordisk: September 11 Could See A Big U.S. Market Catalyst

Novo Nordisk is big pharma with a CAGR of 20.83% over the last 20 years - and rock solid fundamentals.

Comment?

Related Topix: Biotech, Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Teva Pharmaceutical Industries

Fri Aug 08, 2014

Seeking Alpha

Novo Nordisk A/S's (NVO) CEO Lars SA rensen on Q2 2014 Results - Earnings Call Transcript

Jesper Brandgaard - Chief Financial Officer, Executive Vice President, Chairman of the Board - Novo Nordisk Engineering A/S and Chairman of the Board - Novo Nordisk IT A/S But apart from that, I'd like to welcome you all to the Novo Nordisk half year conference call and investor meeting here in London.

Comment?

Related Topix: Biotech

GlobeNewswire

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,...

In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Comment?

Related Topix: Biotech

Thu Aug 07, 2014

Investor's Business Daily

Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

Earnings reports from specialty drugmakers continued to roll in Thursday, as two leading stocks stumbled in the early going on the stock market today .

Comment?

Related Topix: Dey, Biotech, Startups, Medicine, Pharmaceuticals, Mylan Laboratories, Healthcare Industry, Financial Markets, Healthcare Law, Law, Food and Drug Administration

Seeking Alpha

Novo Nordisk A/S (NVO) Q2 2014 Results - Earnings Call Webcast

The following audio is from a conference call that will begin on August 07, 2014 at 07:00 AM ET.

Comment?

Related Topix: Biotech

Reuters

UPDATE 1-Novo Nordisk keeps 2014 outlook, sets FDA date for Tresiba

Denmark's Novo Nordisk , the world's top maker of insulin, maintained its 2014 outlook on Thursday and set a date for when it would submit to the U.S. Food and Drug Administration an analysis to back a crucial future drug.

Comment?

Related Topix: Biotech, Food and Drug Administration

Reuters

Novo Nordisk results in line with expectations, keeps outlook

Denmark's Novo Nordisk , the world's top maker of insulin, posted on Thursday second-quarter operating profit in line with forecasts and maintained its operating profit and sales growth outlook.

Comment?

Related Topix: Biotech

Wed Aug 06, 2014

Reuters

What to Watch in The Day Ahead; Thursday, August 7

Global exchange and clearing house operator Intercontinental Exchange is expected to report a drop in second-quarter earnings, in part due to lower average daily volumes for energy futures.

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, U.S. Environmental Protection Agency

Tue Aug 05, 2014

Local Tech Wire

Latest news on Microsoft, Apple, GSK, municipal broadband, Google and MCS

In the latest Bulldog roundup of life science and technology news: The real difference between Microsoft and Apple; Novo Nordisk leapfrogs Glaxo as U.K. drug giant declines; U.S. Map shows more community-owned broadband networks than expected; Google email scan leads to sex offender arrest; and Metrics Contract Services adopt new name and logo.

Comment?

Related Topix: Google, Startups, Biotech

Seeking Alpha

China Biologic Products Earnings Preview

With the Q2 earnings report taking place after the market closes on August 5, here is what you need to know about this stock.

Comment?

Related Topix: Biotech, China Biologic Products

Mon Jul 28, 2014

Hispanic Business

Novo Resources Strategizes Moving Beatons Creek toward Bankable Feasibility

Both samples were taken from diamond drill core from holes drilled within the 421,000 troy ounces gold inferred resource at Grant's Hill .

Comment?

Related Topix: Biotech

Fri Jul 25, 2014

Reuters

Novo wins EU recommendation for two-in-one diabetes drug

A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

Comment?

Related Topix: Medicine, Health, Diabetes, Biotech, Insulin (generic), Humulin, Novolin

Thu Jul 24, 2014

Seeking Alpha

This Year's Hottest Healthcare ETFs

As a sector, health care has a lot to offer in terms of fundamental and technical data that supports ongoing innovation and profitability.

Comment?

Related Topix: Health Insurance, Health, Financial Markets, Allergan, Biotech

Hispanic Business

Novo Resources Strategizes Moving Beatons Creek Toward Bankable Feasibility

Both samples were taken from diamond drill core from holes drilled within the 421,000 troy ounces gold inferred resource at Grant's Hill .

Comment?

Related Topix: Biotech

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••